Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20104809 | 1.00 | TSHR (0.56) | TSHRCYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL20198601 | 1.00 | TSHR (0.56) | TSHRCYP1A2USP2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7609840 | 0.98 | TSHR (0.54) | TSHRCYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL289131 | 0.97 | CYP1A2 (0.52) | TSHRCYP1A2USP2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL3705397 | 0.95 | CYP1A2 (0.50) | TSHRCYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL430341 | 0.92 | — | — | |
| Sulfuric Acid SCHEMBL4208350 | 0.91 | CYP1A2 (0.48) | TSHRCYP1A2USP2ALDH1A1LMNA | |
| Trifluoroacetic Acid SCHEMBL22342626 | 0.88 | USP2 (0.46) | TSHRCYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL4115624 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL16666607 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836074-A | Salts of neurological drugs and uses thereof | 心悦生医股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| US-20170172957-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2017-06-22 | — | — | US | claimed |
| EP-2714029-B1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN INC (US) | 2017-04-12 | — | — | EP | claimed |
| US-9415031-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | claimed |
| US-20140221453-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | claimed |
| US-20120329851-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2012-12-27 | — | — | US | claimed |
| WO-2012166544-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | claimed |
| WO-2012166533-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | claimed |
| US-20120302621-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. | 2012-11-29 | — | — | US | claimed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | claimed |
| EP-1932852-A1 | Novel taxane related peptides and uses thereof | Campiani, Giuseppe (IT) | 2008-06-18 | — | — | EP | claimed |
| US-20040072743-A1 | Pharmaceutical composition of modified pna molecules | PANTHECO A/S (DK) | 2004-04-15 | — | — | US | claimed |
| US-20030157505-A1 | Novel substance library and supramolecular complexes prepared therewith | AVENTIS RESEARCH & TECHNOLOGIES DEUTSCHLAND GMBH & CO. KG | 2003-08-21 | — | — | US | claimed |
| EP-0931038-B1 | NOVEL SUBSTANCE LIBRARY AND SUPRAMOLECULAR COMPLEXES PRODUCED THEREWITH | NANOGEN RECOGNOMICS GMBH (DE) | 2003-04-16 | — | — | EP | claimed |
| US-20020028442-A1 | NOVEL SUBSTANCE LIBRARY AND SUPRAMOLECULAR COMPLEXES PRODUCED THEREWITH | NANOGEN RECOGNOMICS GMBH (DE) | 2002-03-07 | — | — | US | claimed |
| US-5965579-A | ANTAGONISTS OF THE NEUROTENSIN RECEPTORS; INCREASING AFFINITY FOR HUMAN NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-10-12 | — | — | US | claimed |
| EP-0647629-B1 | Neurotensin active substituted 1-naphthylpyrazole-3-carboxamides, their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-07-07 | — | — | EP | claimed |
| US-5723483-A | NEUROTENSIN ANTAGONIST, HYPOTENSIVE AGENTS AND FOR NEUROPSYCHIATRIC DISORDERS | SANOFI (FR) | 1998-03-03 | — | — | US | claimed |
| US-5502059-A | DOPAMINERGIC DYSFUNCTION DISORDERS | SANOFI (FR) | 1996-03-26 | — | — | US | claimed |
| JP-1153663-A | — | — | None | — | — | JP | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816487-A | FC conjugates comprising CD73 inhibitors and uses thereof | 奇达拉治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250084395-A1 | ENGINEERED NITRILASES FOR BIOCATALYSIS | KCAT ENZYMATIC PRIVATE LIMITED (IN) | 2025-03-13 | — | — | US | disclosed |
| CN-118852152-A | Pyridazinone compound and preparation method and application thereof | 国科大杭州高等研究院 | 2024-10-29 | — | — | CN | disclosed |
| CN-118496177-B | Method for preparing kali lazine and intermediate thereof | 北京耀诚惠仁科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118496177-A | Method for preparing kali lazine and intermediate thereof | 北京耀诚惠仁科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024118635-A2 | THERMOSTABLE BINDING SCAFFOLDS | NECTAGEN, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-4297796-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4192512-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220395553-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220332774-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. | 2022-10-20 | — | — | US | disclosed |
| US-20220324909-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324911-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324925-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220305079-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-09-29 | — | — | US | disclosed |
| US-20220306691-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11453701-B2 | Tau aggregation peptide inhibitors | ADRX, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4058465-A1 | CXCR4 ANTAGONIST PEPTIDES | Cohbar Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022183053-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| CN-114980933-A | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220226484-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-07-21 | — | — | US | disclosed |
| CN-114728937-A | Compositions and methods for treating respiratory syncytial virus | 奇达拉治疗公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4017529-A2 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4013440-A1 | THERAPEUTIC PEPTIDES | Cohbar Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114599389-A | Variant FC domains and uses thereof | 奇达拉治疗公司 | 2022-06-07 | — | — | CN | disclosed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114401731-A | Compositions and methods for treating human immunodeficiency virus | 奇达拉治疗公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114390929-A | Compositions and methods for treating respiratory syncytial virus | 奇达拉治疗公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114302741-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2022-04-08 | — | — | CN | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022032175-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3917944-A1 | THERAPEUTIC PEPTIDES | Cohbar Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021236650-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20210363187-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2021-11-25 | — | — | US | disclosed |
| WO-2021211784-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| CN-113518784-A | Therapeutic peptides | 科巴公司 | 2021-10-19 | — | — | CN | disclosed |
| US-11117930-B2 | Peptide inhibitors of transcription factor aggregation | ADRX, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11111271-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| WO-2021155194-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| CN-113194983-A | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2021097256-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021081110-A2 | PEPTIDES AND USE THEREOF | ANEXIGEN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021030794-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030469-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030752-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030799-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030687-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030749-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030792-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| CN-112074298-A | Langerin+Cell targeting | 马克斯·普朗克科学促进协会 | 2020-12-11 | — | — | CN | disclosed |
| US-20200262834-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-08-20 | — | — | US | disclosed |
| WO-2020160003-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200216495-A1 | TAU AGGREGATION PEPTIDE INHIBITORS | ADRX, INC. | 2020-07-09 | — | — | US | disclosed |
| EP-3668886-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | Adrx, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200181197-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2020-06-11 | — | — | US | disclosed |
| CN-111225984-A | Nucleic acid probe, method for immobilizing nucleic acid to solid support using UV light, solid support comprising immobilized nucleic acid probe, and test device comprising solid support | 硕腾服务有限责任公司 | 2020-06-02 | — | — | CN | disclosed |
| EP-3634978-A1 | TAU AGGREGATION INHIBITORS | Adrx, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-110997693-A | Tau aggregation inhibitors | 阿德克斯公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20200062804-A1 | PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION | ADRX, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190345190-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3519431-A1 | THERAPEUTIC MOTS-C RELATED PEPTIDES | Cohbar Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-110072883-A | The relevant peptide of therapeutic MOTS-C | 科巴公司 | 2019-07-30 | — | — | CN | disclosed |
| WO-2019036725-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | ADRX, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018226992-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018156892-A1 | PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION | ADRX, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| US-9988382-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988382-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| CN-106543017-B | A kind of preparation method of 4 aminocyclohexyl acetic acid | 中国科学院青岛生物能源与过程研究所 | 2018-04-06 | — | — | CN | disclosed |
| CN-106543017-B | A kind of preparation method of 4 aminocyclohexyl acetic acid | 中国科学院青岛生物能源与过程研究所 | 2018-04-06 | — | — | CN | disclosed |
| WO-2018064098-A1 | THERAPEUTIC MOTS-C RELATED PEPTIDES | COHBAR, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| CN-104470899-B | The 4 isoquinolinol compounds as HIF hydroxylase inhibitors | 菲布罗根有限公司 | 2017-12-26 | — | — | CN | disclosed |
| US-20170349586-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349586-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170172957-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9629789-B2 | Rosacea treatments using polymetal complexes | OBAGI MEDICAL PRODUCTS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2714029-B1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| CN-106543017-A | A kind of preparation method of 4 aminocyclohexyl acetic acid | 中国科学院青岛生物能源与过程研究所 | 2017-03-29 | — | — | CN | disclosed |
| CN-106543017-A | A kind of preparation method of 4 aminocyclohexyl acetic acid | 中国科学院青岛生物能源与过程研究所 | 2017-03-29 | — | — | CN | disclosed |
| US-9593138-B2 | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof | WAYNE STATE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9556113-B2 | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | THE SOUTH DAKOTA BOARD OF REGENTS (US) | 2017-01-31 | — | — | US | disclosed |
| US-9540620-B2 | Methods and compositions for modulating G-alpha-Q signaling | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9458198-B1 | Cyclic peptide-based NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9458198-B1 | Cyclic peptide-based NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9457035-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9427397-B2 | Rosacea treatments and kits for performing them | OBAGI MEDICAL PRODUCTS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9415031-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9409892-B2 | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-1816116-B3 | Chemical compositions and methods of making them | OMP INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160184354-A1 | ROSACEA TREATMENTS AND KITS FOR PERFORMING THEM | JR CHEM, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | SANFORD RESEARCH | 2015-11-05 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150218538-A1 | Methods and Compositions for Modulating G-Alpha-Q Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| CN-104470899-A | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors | FIBROGEN INC | 2015-03-25 | — | — | CN | disclosed |
| US-8952057-B2 | Compositions for anorectal use and methods for treating anorectal disorders | JR CHEM, LLC (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140288294-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140248221-A1 | COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140228744-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140221453-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| CN-103946686-A | Long rigid spacers to enhance binding kinetics in immunoassays | KONINKL PHILIPS NV | 2014-07-23 | — | — | CN | disclosed |
| CN-103930783-A | Particle repulsion to enhance surface contact in magnetic particle immunoassays | KONINKL PHILIPS ELECTRONICS NV | 2014-07-16 | — | — | CN | disclosed |
| US-8741955-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735451-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140134119-A1 | ROSACEA TREATMENTS USING POLYMETAL COMPLEXES | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2014-05-15 | — | — | US | disclosed |
| EP-2718299-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR Chem, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8697861-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140100173-A1 | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-04-10 | — | — | US | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-1807118-B1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HARBOR BIOSCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1907403-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-1816116-B1 | Chemical compositions and methods of making them | JR CHEMICALS (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013165554-A1 | METHODS AND COMPOSITIONS FOR MODULATING G-ALPHA-Q SIGNALING | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-11-07 | — | — | WO | disclosed |
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130090302-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090299-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130039869-A1 | ROSACEA TREATMENTS AND KITS FOR PERFORMING THEM | JR CHEM, LLC (US) | 2013-02-14 | — | — | US | disclosed |
| US-8367646-B2 | Steroid compounds and treatment methods | Harbor Therapeutics, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120329851-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2012174076-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120315223-A1 | COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC | 2012-12-13 | — | — | US | disclosed |
| US-20120315224-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC | 2012-12-13 | — | — | US | disclosed |
| US-8329926-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2012166544-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166533-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120302621-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. | 2012-11-29 | — | — | US | disclosed |
| US-8318701-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012096839-A1 | COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS | JR CHEM, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120177582-A1 | COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS | JR CHEM, LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120177583-A1 | COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS | JR CHEM, LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| EP-2043658-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120071454-A1 | Steroid Compounds and Treatment Methods | HARBOR BIOSCIENCES, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-8106036-B2 | Pharmaceutical compositions-4 | HARBOR BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | NOVO NORDISK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| US-8076316-B2 | Steroid compounds and formulations | HARBOR BIOSCIENCES, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | FRINCKE JAMES M | 2011-09-08 | — | — | US | disclosed |
| EP-2356141-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-08-17 | — | — | EP | disclosed |
| EP-2346892-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178318-A1 | METHODS OF MAKING BIMETAL COMPLEXES | RAMIREZ JOSE E | 2011-07-21 | — | — | US | disclosed |
| EP-1778702-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7973163-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2322182-A1 | Androstenol derivatives as androgen receptor modulator | Harbor BioSciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| CN-101146530-B | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG | 2011-05-18 | — | — | CN | disclosed |
| US-7943770-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7935839-B2 | Sepsis treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110098260-A1 | Steroid Compounds and Formulations | HARBOR BIOSCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | BOOJAMRA CONSTANTINE G | 2011-03-24 | — | — | US | disclosed |
| US-7910571-B2 | 3 beta -hydroxy-16 alpha -fluoro-17 beta -aminoandrost-5-ene; immunostimulant, antiinflammatory agent; neutropenia, infections, blood cell deficiencies; interleukin, tumor necrosis factor, macrophage inflammatory protein, transforming growth factor, cyclooxygenase, and lipoxygenase inhibitor | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7906497-B2 | Cancer treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7897800-B2 | Chemical compositions and methods of making them | JR CHEM, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7871991-B2 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | GILEAD SCIENCES, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
| US-20110008271-A1 | ROSACEA TREATMENTS USING POLYMETAL COMPLEXES | JR CHEM, LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-7863261-B2 | Breast and prostate cancer treatment method | HARBOR BIOSCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7842672-B2 | Phosphonate inhibitors of HCV | GILEAD SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-0719273-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20100240633-A1 | Cancer treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-7776845-B2 | Pharmaceutical compositions | HARBOR BIOSCIENCES, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2010085753-A1 | ROSACEA TREATMENTS AND KITS FOR PERFORMING THEM | JR CHEM, LLC (US) | 2010-07-29 | — | — | WO | disclosed |
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-7723532-B2 | Pharmaceutical compositions 3 | HARBOR BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2010055135-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055136-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7696189-B1 | Prostate and breast cancer treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7691835-B2 | Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2166018-A2 | Antibody binding affinity ligands | Novo Nordisk A/S (DK) | 2010-03-24 | — | — | EP | disclosed |
| EP-1831243-B1 | ANTIBODY BINDING AFFINITY LIGANDS | NOVO NORDISK AS (DK) | 2010-03-17 | — | — | EP | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090270625-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | CANNIZZARO CARINA | 2009-09-10 | — | — | US | disclosed |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | BIOVIE INC. | 2009-08-27 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090202470-A1 | Phosphonate Analogs of Hiv Inhibitor Compounds | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090156558-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | FARDIS MARIA | 2009-06-18 | — | — | US | disclosed |
| US-7547687-B2 | Therapeutic treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7524835-B2 | Tetrol steroids and esters | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| US-7482334-B2 | Therapeutic treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090012037-A1 | Antiviral Compounds | GILEAD SCIENCE, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080311681-A1 | Antibody Binding Affinity Ligands | VERSAMATRIX A/S (DK) | 2008-12-18 | — | — | US | disclosed |
| US-20080311077-A1 | Antiviral Compounds | GILEAD SCIENCES, INC. | 2008-12-18 | — | — | US | disclosed |
| US-7462608-B2 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7439350-B2 | Nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432273-B2 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7427636-B2 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427624-B2 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1955700-A2 | Therapeutic treatment of androgen receptor driven conditions | Hollis-Eden Pharmaceuticals Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | BIOVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176823-A1 | Breast and Prostate Cancer Treatment Method | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080171724-A1 | Phosphonate Derivatives of Mycophenolic Acid | GILEAD SCIENCES, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080167270-A1 | ANTI-INFECTIVE PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2008-07-10 | — | — | US | disclosed |
| US-7396827-B2 | Pharmaceutical compositions and treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | disclosed |
| EP-1932852-A1 | Novel taxane related peptides and uses thereof | Campiani, Giuseppe (IT) | 2008-06-18 | — | — | EP | disclosed |
| CN-101193852-A | 4-Hydroxyisoleucine analogs and uses thereof | INNODIA INC (CA) | 2008-06-04 | — | — | CN | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080090791-A1 | Cystic fibrosis treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080085873-A1 | Disease treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1907403-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1906971-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1904506-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080076740-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| CN-101146530-A | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG (CH) | 2008-03-19 | — | — | CN | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058301-A1 | Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080045490-A1 | Pharmaceutical Compositions | BIOVIE INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080021006-A1 | Pharmaceutical Compositions | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1879657-A2 | USE OF COMPOUNDS TO ENHANCE PROCESSIVITY OF TELOMERASE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2008-01-23 | — | — | EP | disclosed |
| US-20080015174-A1 | Metabolic Disease Treatments | BIOVIE INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005542-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC., (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070275938-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275937-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-7300924-B2 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070265236-A1 | Asthma Treatment Methods | BIOVIE INC. | 2007-11-15 | — | — | US | disclosed |
| EP-1509537-B9 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20070213309-A1 | Sepsis Treatment Methods | BIOVIE INC. | 2007-09-13 | — | — | US | disclosed |
| EP-1831243-A2 | ANTIBODY BINDING AFFINITY LIGANDS | Novo Nordisk A/S (DK) | 2007-09-12 | — | — | EP | disclosed |
| EP-1832598-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070203107-A1 | Pharmaceutical compositions | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203354-A1 | Chemical Compositions and Methods of Making Them | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-30 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1816116-A1 | Chemical compositions and methods of making them | JR Chemicals (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7253006-B2 | Device and method for manufacturing bead array, and method for detecting target substance | SEIKO EPSON CORPORATION (JP) | 2007-08-07 | — | — | US | disclosed |
| WO-2007084157-A2 | NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1809299-A2 | PHOSPHONATE SUBSTITUTED KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1809277-A2 | PHOSPHONATE DERIVATIVES OF MYCOPHENOLIC ACID | GILEAD SCIENCES, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1509537-B1 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| EP-1778249-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1778251-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1778702-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1539183-A4 | THERAPEUTIC TREATMENT METHODS | HOLLIS EDEN PHARMACEUTICALS (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20070078081-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070072809-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2006110157-A9 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES INC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | GILEAD SCIENCES, INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1575486-A4 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007014352-A2 | ANTIVIRAL PHOSPHONATE CONJUGATES FOR INHIBITION OF HIV | GILEAD SCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007011658-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009109-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1715871-A1 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006114065-A2 | USE OF COMPOUNDS TO INHIBIT NEOPLASIA | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY A CADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114064-A2 | USE OF COMPOUNDS TO ENHANCE PROCESSIVITY OF TELOMERASE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110157-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006102594-A1 | NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1680129-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS AS PHOSPHONATE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006066598-A2 | ANTIBODY BINDING AFFINITY LIGANDS | NOVO NORDISK A/S (DK) | 2006-06-29 | — | — | WO | disclosed |
| US-20060128692-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC (US) | 2006-06-15 | — | — | US | disclosed |
| US-20060122123-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1663254-A2 | ANTI-INFLAMATORY PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20060115815-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006047661-A2 | PHOSPHONATE DERIVATIVES OF MYCOPHENOLIC ACID | GILEAD SCIENCES, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006047507-A2 | PHOSPHONATE SUBSTITUTED KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20060079492-A1 | Compositions and treatment methods | BIOVIE INC. | 2006-04-13 | — | — | US | disclosed |
| US-20060063749-A1 | Pharmaceutical compositions and treatment methods - 5 | BIOVIE INC. | 2006-03-23 | — | — | US | disclosed |
| EP-1628685-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2006020276-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. | 2006-02-16 | — | — | US | disclosed |
| WO-2006015261-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1620109-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1620110-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1620445-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050282732-A1 | Pharmaceutical compositions and treatment methods-7 | BIOVIE INC. | 2005-12-22 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050261237-A1 | Nucleoside phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| CN-1228312-C | Process for synthesizing beta-amino acid using ketone as raw material | CHINESE ACAD INST CHEMISTRY (CN) | 2005-11-23 | — | — | CN | disclosed |
| US-20050256095-A1 | Asthma and colitis treatment methods | BIOVIE INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. | 2005-10-13 | — | — | US | disclosed |
| US-20050215525-A1 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1575486-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20050176758-A1 | 2-(hydroxy or methoxymethoxy)-4-(carboxy or alkoxycarbonyl)-5-(fluoro or hydrogen)-7-oxabicyclo(4.1.0)hept-3-ene chemical intermediates to neuraminidase inhibitors | GILEAD SCIENCES, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20050159366-A1 | Pharmaceutical compositions and treatment methods - 8 | BIOVIE INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050153990-A1 | Phosphonate substituted kinase inhibitors | GILEAD SCIENCES, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005063258-A1 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1539183-A1 | THERAPEUTIC TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005044308-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | GILEAD SCIENCES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044279-A1 | PURINE NUCLEOSIDE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101581-A1 | Therapeutic treatment methods 2 | BIOVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005039552-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS AS PHOSPHONATE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050079592-A1 | Device and method for manufacturing bead array, and method for detecting target substance | SEIKO EPSON CORPORATION (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20050075321-A1 | Neurological disorder treatment methods | BIOVIE INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1501841-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040242465-A1 | Nucleotide analogs | BISCHOFBERGER NORBERT W (US) | 2004-12-02 | — | — | US | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096285-A2 | ANTI-INFECTIVE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096818-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096233-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096234-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096287-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096237-A2 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220114-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220161-A1 | Pharmaceutical compositions and treatment methods-6 | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
| CN-1511826-A | Process for synthesizing beta-amino acid using ketone as raw material | 中国科学院化学研究所 | 2004-07-14 | — | — | CN | disclosed |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040116359-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1422234-A2 | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | BIOVIE INC. | 2004-05-20 | — | — | US | disclosed |
| US-20040072743-A1 | Pharmaceutical composition of modified pna molecules | PANTHECO A/S (DK) | 2004-04-15 | — | — | US | disclosed |
| US-20040053999-A1 | Novel compounds and methods for synthesis and therapy | BISCHOFBERGER NORBERT W (US) | 2004-03-18 | — | — | US | disclosed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6667299-B1 | 16-alpha-bromo-3-beta-hydroxy-5-alpha-androstan-17-one hemihydrate; 16-alpha-bromoepiandrosterone; steroid; immune modulator | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091264-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1228083-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6376674-B1 | BACTERICIDES; VIRICIDES | GILEAD SCIENCES, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1163256-A1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-20010041794-A1 | Nucleotide analogs | GILEAD SCIENCES, INC. | 2001-11-15 | — | — | US | disclosed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| US-6225341-B1 | FOR INHIBITING NEURAMINIDASE; FOR THERAPY AND PROPHYLAXIS OF VIRUS INFECTION | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2001023405-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| US-6172239-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 2001-01-09 | — | — | US | disclosed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| EP-1015417-A1 | COMPOUNDS CONTAINING SIX-MEMBERED RINGS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GILEAD SCIENCES, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000029385-A1 | 1,4,5,6-TETRAHYDRO-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEURAMINIDASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2000-05-25 | — | — | WO | disclosed |
| EP-0759917-B1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES INC (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0976734-A2 | Selective inhibitors of viral or bacterial neuraminidase | GILEAD SCIENCES, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0968178-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBICIDES | Novartis AG (CH) | 2000-01-05 | — | — | EP | disclosed |
| US-5994377-A | NEURAMINIDASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5965579-A | ANTAGONISTS OF THE NEUROTENSIN RECEPTORS; INCREASING AFFINITY FOR HUMAN NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5958973-A | Polyhydroxy benzoic acid derivatives and their use as neuraminidase inhibitors | GILEAD SCIENCES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5952375-A | NEURAMINIDASE INHIBITOR FOR INHIBITION OF VIRUSES, IN PARTICULAR INFLUENZA VIRUSES; FDA ORANGE BOOK LISTED PATENT FOR OSELTAMIVIR PHOSPHATE | GILEAD SCIENCES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0938475-A1 | PIPERIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5939449-A | NOVEL COMPOUNDS HAVING HIGH AFFINITY FOR THE NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-08-17 | — | — | US | disclosed |
| US-5936123-A | COMPOUNDS SUCH AS 3-ISOPROPYL-4-HYDRAZINOBENZOIC ACID AND ITS SALTS | SANOFI (FR) | 1999-08-10 | — | — | US | disclosed |
| US-5925661-A | NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 1999-07-20 | — | — | US | disclosed |
| WO-1999014185-A1 | COMPOUNDS CONTAINING SIX-MEMBERED RINGS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GILEAD SCIENCES, INC. (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999010365-A2 | 5',5'-LINKED OLIGOMERS HAVING ANTI-THROMBIN ACTIVITY | GILEAD SCIENCES, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5866601-A | ACID CYCLOHEXENE DERIVATIVES, NEURAMINIDASE INHIBITORS SUCH AS OSELTAMIVIR | GILEAD SCIENCES, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5834431-A | Des-Arg9 -BK antagonists | CORTECH, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| WO-1998038160-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBICIDES | NOVARTIS AG (CH) | 1998-09-03 | — | — | WO | disclosed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0848718-A1 | CYTOLYTIC BRADYKININ ANTAGONISTS | CORTECH, INC. (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5767100-A | ADMINISTERING NUCLEOTIDE ANALOGUES TO TREAT HERPES VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5763483-A | NEURAMINIDASE INHIBITOR TREATING INFLUENZA VIRUS INFECTION; OSELTAMIVIR OR THE FREE ACID THEREOF; FDA ORANGE BOOK LISTED PATENT FOR OSELTAMIVIR PHOSPHATE | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5756486-A | CYCLIZED NUCLEOTIDE; VIRICIDE | GILEAD SCIENCES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5750729-A | REACTING PROTECTED PYRAN DERIVATIVES TO FORM NUCLEOTIDES | GILEAD SCIENCES,INC. (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1998017647-A1 | PIPERIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| US-5723483-A | NEUROTENSIN ANTAGONIST, HYPOTENSIVE AGENTS AND FOR NEUROPSYCHIATRIC DISORDERS | SANOFI (FR) | 1998-03-03 | — | — | US | disclosed |
| US-5693771-A | REACTING PROTECTED PYRAN COMPOUND WITH PHOSPHITE AND HETEROCYCLIC BASE | GILEAD SCIENCES, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0807118-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997009346-A1 | DES-ARG9-BK ANTAGONISTS | CORTECH, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1997009347-A1 | CYTOLYTIC BRADYKININ ANTAGONISTS | CORTECH, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| EP-0759917-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5591851-A | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| US-5585497-A | USEFUL IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS, ESPECIALLY THOSE ASSOCIATED WITH A DYSFUNCTION OF THE DOPAMINERGIC SYSTEMS | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
| WO-1996026933-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5523455-A | PREPARED USING A NAPHTHYLHYDRAZINE CHEMICAL INTERMEDIATE | SANOFI (FR) | 1996-06-04 | — | — | US | disclosed |
| WO-1996016081-A1 | BRADYKININ ANTAGONIST PEPTIDES CONTAINING INDANE-SUBSTITUTED AMINO ACIDS | UNIVERSITY TECHNOLOGY CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| US-5502059-A | DOPAMINERGIC DYSFUNCTION DISORDERS | SANOFI (FR) | 1996-03-26 | — | — | US | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| JP-H01153663-A | HYPOTENSOR | AJINOMOTO CO INC | 1989-06-15 | — | — | JP | disclosed |
| US-4368237-A | ORGANIC SOLVENT-FREE | FUJI PHOTO FILM CO., LTD. (JP) | 1983-01-11 | — | — | US | disclosed |
| US-4242783-A | Calender roll for use in super calender for magnetic tapes | FUJI PHOTO FILM CO., LTD. (JP) | 1981-01-06 | — | — | US | disclosed |
| US-4187374-A | 7-(β-Aminoacylamino)-3-substituted-3-cephem-4-carboxylic acid derivatives and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-05 | — | — | US | disclosed |
| US-4128673-A | Method for super calendering magnetic recording elements | FUJI PHOTO FILM CO., LTD. (JP) | 1978-12-05 | — | — | US | disclosed |
| US-4127570-A | BACTERICIDE | BEECHAM GROUP LIMITED (GB) | 1978-11-28 | — | — | US | disclosed |
| US-4094872-A | 7-(β-Aminoacylamino)-3-heterocyclic-thiomethyl-3-cephem-4-carboxylic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-06-13 | — | — | US | disclosed |
| US-3932391-A | Cephalosporin isocyanates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
| US-3932391-A | Cephalosporin isocyanates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275938-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | TSHR 2465/4885CYP1A2 206/4885USP2 3720/4885 |
| US-20040242465-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | TSHR 2855/4885CYP1A2 4728/4885USP2 4311/4885 |
| US-20070275937-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | TSHR 2465/4885CYP1A2 206/4885USP2 3720/4885 |
| US-20060128692-A1 | Non nucleoside reverse transcriptase inhibitors | TYMP, PNP, ITPA | TSHR 3903/4885CYP1A2 3713/4885USP2 4304/4885 |
| US-20090156558-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | TYMP, PHOSPHO1, PHPT1 | TSHR 2471/4885CYP1A2 4357/4885USP2 4752/4885 |
| US-20140228744-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | FABP6, ALPI, KRT18 | TSHR 4286/4885CYP1A2 4409/4885USP2 1859/4885 |
| US-20090202470-A1 | Phosphonate Analogs of Hiv Inhibitor Compounds | PIK3CA, TYMP, ITPA | TSHR 4872/4885CYP1A2 4641/4885USP2 4430/4885 |
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | INPP5D, INPPL1, MTAP | TSHR 4831/4885CYP1A2 2013/4885USP2 2473/4885 |
| US-20110098260-A1 | Steroid Compounds and Formulations | AR, NR5A1, CYP17A1 | TSHR 1135/4885CYP1A2 379/4885USP2 3488/4885 |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | PHOSPHO1, NFATC1, IFNG | TSHR 4615/4885CYP1A2 4725/4885USP2 4008/4885 |
| US-20050153990-A1 | Phosphonate substituted kinase inhibitors | PIK3CA, PNKP, PIK3CB | TSHR 2253/4885CYP1A2 4597/4885USP2 2798/4885 |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | SLC18A2, SLC6A2, SLC18A1 | TSHR 1602/4885CYP1A2 212/4885USP2 3385/4885 |
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | TSHR 2879/4885CYP1A2 120/4885USP2 3609/4885 |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | TSHR 4568/4885CYP1A2 4769/4885USP2 3392/4885 |
| US-20080167270-A1 | ANTI-INFECTIVE PHOSPHONATE ANALOGS | PHOSPHO1, PGLS, PSPH | TSHR 4310/4885CYP1A2 4574/4885USP2 4449/4885 |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, ITPA | TSHR 4801/4885CYP1A2 4700/4885USP2 3564/4885 |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | TYMP, PNP, NUDT1 | TSHR 3423/4885CYP1A2 3885/4885USP2 4841/4885 |
| US-20070072809-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | TSHR 4829/4885CYP1A2 3096/4885USP2 2135/4885 |
| US-20080045490-A1 | Pharmaceutical Compositions | HSD3B1, HSD17B3, HSD17B1 | TSHR 2747/4885CYP1A2 99/4885USP2 3376/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | TSHR 4568/4885CYP1A2 4769/4885USP2 3392/4885 |
| US-20120315224-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | FABP6, ALPI, KRT18 | TSHR 4286/4885CYP1A2 4409/4885USP2 1859/4885 |
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | TSHR 2359/4885CYP1A2 131/4885USP2 3033/4885 |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | HSD3B2, HSD3B1, HSD17B2 | TSHR 3575/4885CYP1A2 58/4885USP2 1301/4885 |
| US-20100240633-A1 | Cancer treatment methods | AR, KLK3, ACP3 | TSHR 1256/4885CYP1A2 3002/4885USP2 2159/4885 |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | TSHR 4748/4885CYP1A2 2040/4885USP2 1074/4885 |
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | TSHR 4757/4885CYP1A2 4818/4885USP2 2540/4885 |
| US-20010041794-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | TSHR 2855/4885CYP1A2 4728/4885USP2 4311/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | TSHR 4568/4885CYP1A2 4769/4885USP2 3392/4885 |
| US-20080015174-A1 | Metabolic Disease Treatments | HSD3B1, HSD17B1, CYP27A1 | TSHR 1740/4885CYP1A2 131/4885USP2 2771/4885 |
| US-20120071454-A1 | Steroid Compounds and Treatment Methods | AR, NR5A1, CYP17A1 | TSHR 1225/4885CYP1A2 999/4885USP2 2982/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | TSHR 1774/4885CYP1A2 298/4885USP2 3821/4885 |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | PHOSPHO1, NFATC1, IFNG | TSHR 4615/4885CYP1A2 4725/4885USP2 4008/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | TSHR 4757/4885CYP1A2 4818/4885USP2 2540/4885 |
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | TSHR 4486/4885CYP1A2 1912/4885USP2 3643/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | TSHR 4568/4885CYP1A2 4769/4885USP2 3392/4885 |
| US-20050282732-A1 | Pharmaceutical compositions and treatment methods-7 | HSD17B7, IL17A, HSD3B1 | TSHR 2683/4885CYP1A2 177/4885USP2 2820/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | TSHR 4757/4885CYP1A2 4818/4885USP2 2540/4885 |
| US-20050215525-A1 | Anti-infective phosphonate analogs | PHOSPHO1, PGLS, PSPH | TSHR 4310/4885CYP1A2 4574/4885USP2 4449/4885 |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | TSHR 2242/4885CYP1A2 117/4885USP2 3098/4885 |
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | PHOSPHO1, G6PC1, PC | TSHR 2537/4885CYP1A2 2378/4885USP2 4486/4885 |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HSD3B1, HSD3B2, HSD17B13 | TSHR 3015/4885CYP1A2 100/4885USP2 3940/4885 |
| US-20070203354-A1 | Chemical Compositions and Methods of Making Them | PARG, PCBP1, POLI | TSHR 4738/4885CYP1A2 852/4885USP2 3143/4885 |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | PPP5C, PPP3CA, PPP4R3A | TSHR 3549/4885CYP1A2 4196/4885USP2 4651/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | TSHR 2172/4885CYP1A2 96/4885USP2 3457/4885 |
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | FCGR1A, FCGR2A, FCGR3B | TSHR 254/4885CYP1A2 4808/4885USP2 3623/4885 |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | TSHR 4872/4885CYP1A2 4641/4885USP2 4430/4885 |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | EIF2AK2, PNP, NUDT1 | TSHR 4304/4885CYP1A2 1389/4885USP2 2691/4885 |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | PIK3CA, PNKP, PIK3CB | TSHR 3334/4885CYP1A2 4837/4885USP2 3189/4885 |
| US-20080311077-A1 | Antiviral Compounds | EIF2AK2, MAVS, ITPA | TSHR 4801/4885CYP1A2 4700/4885USP2 3564/4885 |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | TSHR 4612/4885CYP1A2 4016/4885USP2 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.